FreeScore your brand plan before management does. Send me the scorecard
In short: a go-to-market strategy answers nine decisions before you spend the launch budget: the market and the job to be done, the first target customers, the value proposition, the offer and price, the route to market, the messages and evidence, the sales and promotion model, the launch sequence, and the measures of success. In pharma and consumer health, regulation sits on top: registration, pricing approval and promotion rules shape every decision. The strategy fits on one page; if it does not, the decisions are not made yet.
Most failed launches do not fail because the product was bad. They fail because the product was not on the shelf when the advertising started, because the sales team was talking to everyone instead of the customers most likely to try it, or because the price approval came three months after the launch meeting. A go-to-market strategy exists to prevent exactly these failures: it forces the decisions and the order of work before money is spent.
This guide explains what a go-to-market (GTM) strategy is, the nine decisions it must answer, the frameworks that help answer them, how the route differs for prescription and OTC products, the sequence a launch follows in Saudi Arabia, a timeline, the measures to track, the common mistakes, and a one-page template. For a full worked example in one market, read the guide to launching an OTC product in Saudi Arabia.
What Is a Go-to-Market Strategy?
A GTM strategy is the plan for how one product reaches one set of customers and wins, with a clear sequence and measures. It is narrower and more time-bound than a marketing strategy.
A go-to-market strategy describes how a company will bring a specific product to a specific market: who it is for, why they should choose it, how they will get it, what it costs, how they will hear about it, and how the company will know whether it is working. It is used for a new product launch, a new indication or format, entry into a new country, or a move into a new channel such as e-commerce.
The difference from a marketing strategy is scope and time. A pharma marketing strategy sets how a brand or portfolio competes over years. A GTM strategy is tied to one moment of entry and covers the operational decisions that moment needs: supply, registration, pricing, listings, sales force, launch materials and launch metrics. The two must agree: the GTM strategy is how the long-term positioning first meets the market.
| Marketing strategy | Go-to-market strategy | Launch plan | |
|---|---|---|---|
| Question | How does the brand compete over time? | How does this product enter this market and win? | Who does what, by when? |
| Horizon | Three to five years | Pre-launch to the first year or two | Weeks and months around launch |
| Output | Positioning, portfolio roles, long-term goals | Target, value proposition, route, price, sequence, KPIs | Task list, owners, dates, budget lines |
What Are the Nine Decisions in a Go-to-Market Strategy?
Every GTM strategy, in any industry, answers the same nine questions. In health products, each one has a regulatory constraint attached.
| # | Decision | The question to answer | Health product constraint |
|---|---|---|---|
| 1 | Market and job to be done | Which problem, in which market, are we solving? | The approved indication defines the problem you may claim to solve |
| 2 | Target customers | Who chooses, uses and pays, and which group do we win first? | Prescribers, pharmacists, patients, payers and retailers each decide something different |
| 3 | Value proposition and positioning | Why us over the alternatives, in one sentence? | Every claim needs evidence and approval |
| 4 | Offer and price | What exactly do we sell, in which packs, at what price? | Prices may need regulator approval; margins may be set by rule |
| 5 | Route to market | Through which channels and partners does the product reach the customer? | Licensed distributors, pharmacy chains, hospital formularies, online pharmacy rules |
| 6 | Messages and evidence | What do we say to each customer, and what proves it? | Promotion rules differ for Rx and OTC, and by audience |
| 7 | Sales and promotion model | Field force, key accounts, digital, media, in-store: which mix? | Rx media to the public is usually restricted; HCP engagement rules apply |
| 8 | Launch sequence | What happens in which order, and what must be true before we spend? | Registration, pricing and listings come before promotion |
| 9 | Measures of success | Which numbers tell us, early, whether it is working? | Sell-in can mislead; track sell-out and prescriptions where available |
Decisions one to four are strategy: they decide whether the product can win. Decisions five to seven are execution design: they decide how it reaches customers. Decisions eight and nine are control: they decide what happens when, and how you will learn. Skipping any of them shows up later as a launch problem.
Which Frameworks Help Build a Go-to-Market Strategy?
Five classic frameworks cover most of the thinking: Ansoff for the type of move, STP for the target, the marketing mix for the offer, diffusion and the chasm for the sequence, and mental and physical availability for consumer health.
| Framework | Source | What it decides in a GTM strategy |
|---|---|---|
| Product-market matrix | H. Igor Ansoff, Harvard Business Review, 1957 | Whether this is market penetration, product development, market development or diversification, and so how much risk and learning the plan needs |
| Segmentation, targeting, positioning (STP) | Developed in Philip Kotler’s marketing management texts | Which segment to win first and the position to own in its mind |
| Marketing mix (4Ps) | E. Jerome McCarthy, 1960 | Product, price, place and promotion choices for the launch |
| Diffusion of innovations and the chasm | Everett Rogers, 1962; Geoffrey Moore, Crossing the Chasm, 1991 | Who adopts first (innovators and early adopters), and why the step to the mainstream needs a different approach |
| Mental and physical availability | Byron Sharp, How Brands Grow, 2010 | For OTC and consumer health: being easy to think of and easy to find at the moment of need |
The Ansoff check is often skipped, and it matters. Launching a line extension of a known brand into the same pharmacies (market penetration or product development) needs a very different plan from entering a new country with a new brand (market development, or close to diversification). The more of the matrix you move across, the more you should budget for learning, and the more you should stage spending against evidence.
The chasm idea matters in prescription launches. Specialists who follow new evidence closely may adopt early, but most prescribers wait for guidelines, peer experience and formulary listing. A launch that wins early adopters but has no plan for the mainstream stalls after the first year. The guide to the pharmaceutical marketing mix covers the 4Ps in depth.
How Does Go-to-Market Differ for Rx and OTC Products?
Rx launches win prescribers and access; OTC launches win the shelf, the pharmacist’s recommendation and the shopper. The nine decisions are the same; the answers are very different.
| Decision | Prescription (Rx) | OTC and consumer health |
|---|---|---|
| Who chooses | Physician, within formulary and payer rules | Consumer, often guided by the pharmacist |
| Access | Hospital formularies, tenders, insurance coverage | Distributor and chain listings, shelf space, online pharmacies |
| Evidence | Clinical trials, guidelines, health economics | Approved claims, consumer understanding, pharmacist trust |
| Promotion | HCP-directed: field force, MSLs, congresses, digital HCP channels | Pharmacy trade, in-store, consumer media and digital within rules |
| Early KPIs | Formulary listings, prescribers trying the product, new patients | Numeric distribution, shelf presence, pharmacist recommendation, trial |
For prescription products, access usually comes first. A product a physician cannot prescribe in their hospital, or a patient cannot get reimbursed, will not grow however good the promotion is. The guide to market access in the pharmaceutical industry covers that track. For OTC, the pharmacy channel and the shelf decide much of the outcome, which is why the pharmacy planogram and trade terms belong in the GTM strategy, not in a later trade plan.
FreeScore your brand plan before management does. Send me the scorecard
What Is the Go-to-Market Sequence in Saudi Arabia?
Registration, then price, then access and listings, then promotion. Each step has its own lead time, and promotion before availability wastes money.
In Saudi Arabia a medicine needs a marketing authorisation from the Saudi Food and Drug Authority (SFDA) and an approved price before it can be sold. SFDA’s own summary of its pricing process (2024) describes a pricing directorate and committee, a mix of internal and external reference pricing, and set wholesale and pharmacy margins. Government purchasing runs largely through the National Unified Procurement Company (NUPCO), and private insurance coverage sits under the Council of Health Insurance. Rules change, so check the current SFDA, NUPCO and Council requirements for your product category before you set dates.
| Step | What happens | Who you work with | GTM decisions it affects |
|---|---|---|---|
| 1. Registration | Dossier submitted and reviewed; marketing authorisation issued | SFDA, regulatory affairs | Indication, claims, pack, launch date |
| 2. Pricing | Price set by SFDA; margins follow the published rules | SFDA pricing, finance | Offer, pack sizes, profitability, positioning against alternatives |
| 3. Access and listings | Distributor agreement; chain listings; hospital formulary and tender work for Rx | Distributor, chains, hospital committees, NUPCO | Route to market, trade terms, launch accounts |
| 4. Supply and readiness | Stock in market, materials approved, team trained | Supply chain, medical, compliance, sales | Launch date, launch quantity, first targets |
| 5. Launch and promotion | Field, trade, digital and media activity starts | Sales, marketing, agencies | Messages, mix, budget phasing |
| 6. Review and scale | Early KPIs reviewed; budget moved to what works | Brand team, management | Second-wave targets, investment level |
The register itself tells you something about competition. The Saudi drug registration statistics and the Saudi OTC medicines list show how crowded each therapy area and ingredient already is, which is useful input for decisions one, three and four.
What Does a Go-to-Market Timeline Look Like?
Plan backwards from the date the product will be in stock where customers buy it, not from the date of approval.
| Phase | Main work | Gate to pass before moving on |
|---|---|---|
| Insight and choice | Market sizing, customer research, competitor review, first target segment | One-page GTM strategy agreed by marketing, sales, medical and finance |
| Regulatory and pricing | Registration, price submission, claims and materials review | Authorisation and price in hand, approved claims list |
| Access and channel | Distributor terms, chain listings, formulary submissions, launch accounts | Listing confirmed in priority accounts |
| Readiness | Stock, training, materials, CRM targets, launch event plan | Stock in market and team certified |
| Launch window | First wave of field, trade and digital activity in priority accounts | Leading KPIs reviewed at fixed points |
| Scale | Second wave, wider accounts, more channels | Evidence that the first wave works |
The gates are the point. A launch that moves to the next phase without passing the gate, for example starting consumer media before listings are confirmed, pays twice: once for the activity and again for the trust lost with pharmacists and consumers who could not find the product.
Which KPIs Should a Go-to-Market Strategy Track?
Follow the funnel from availability to loyalty. Sales are the last number to move, so do not wait for them to judge the launch.
| Stage | Rx example | OTC example |
|---|---|---|
| Availability | Formulary listings in target hospitals | Numeric distribution in target pharmacies; planogram compliance |
| Awareness and knowledge | Target prescribers reached and message recall | Pharmacist awareness; consumer awareness where measured |
| Trial | Prescribers who have prescribed at least once | First purchases; pharmacist recommendations |
| Repeat | Repeat prescribing, patient persistence | Repeat purchase, rate of sale per store |
| Business result | Sales and share against forecast | Sell-out, share of category, margin |
Define each KPI, its data source and its target before launch, and agree which result triggers which decision (for example, “if distribution in priority chains is below target by the first review, hold consumer media and fix listings first”). The pharma marketing KPI library has formulas and sources for each of these.
What Are the Most Common Go-to-Market Mistakes?
Most come from skipping a decision or breaking the sequence.
| Mistake | What it looks like | Fix |
|---|---|---|
| Targeting everyone | The field force calls on every doctor; the budget is spread thin | Pick the first segment you can win and say no to the rest for the first wave |
| Promotion before availability | Media runs while chains have not listed the product | Make listing confirmation a gate for spend |
| Unapprovable messages | The agency’s campaign is rejected late in review | Start from the approved claims list and involve medical and regulatory early |
| Underestimated lead times | Pricing or formulary decisions arrive months after the planned launch | Plan regulatory, pricing and access as separate tracks with their own owners |
| Spending before evidence | The full year’s budget is committed in the first quarter | Phase the budget and release the second wave against KPIs |
| No agreed measures | Every team reports a different number at the review | One KPI sheet, defined before launch, owned by the brand team |
A One-Page Go-to-Market Strategy Template
Fill one line per decision. If a line takes more than two sentences, the decision is not made yet.
| Decision | Your answer |
|---|---|
| 1. Market and job to be done | The problem, the market, and the Ansoff move this is |
| 2. First target segment | Who we win first, and why them |
| 3. Value proposition | For [segment], [product] is the [frame of reference] that [benefit] because [reason to believe] |
| 4. Offer and price | Packs, price position against alternatives, margins for partners |
| 5. Route to market | Distributor, priority accounts, formularies, online |
| 6. Messages and evidence | Three messages per audience, each with its approved evidence |
| 7. Sales and promotion model | Field, key accounts, trade, digital, media, with budget split |
| 8. Sequence and gates | Phases, dates and the gate each must pass |
| 9. Measures of success | Five KPIs with targets, sources and review dates |
| Risks and constraints | Regulatory, supply, competitive, budget; owner for each |
The value proposition line uses the classic positioning statement structure. The guide to pharma brand positioning shows how to write and test it. Once the one-page strategy is agreed, it becomes the first section of the brand plan and the brief for the launch plan.
Key Takeaways
- A go-to-market strategy is the plan for how one product enters one market and wins; it is narrower and more time-bound than a marketing strategy
- It answers nine decisions: market, target, value proposition, offer and price, route, messages, promotion model, sequence and measures
- Ansoff, STP, the 4Ps, diffusion and the chasm, and mental and physical availability cover most of the thinking
- Rx launches win access and prescribers; OTC launches win listings, shelf, pharmacist recommendation and shoppers
- In Saudi Arabia, registration and SFDA pricing come first, then listings and formularies, then promotion
- Use gates: do not spend on promotion until the product is available where customers buy
- Track availability, awareness, trial and repeat before judging the launch on sales
Frequently Asked Questions
What is a go-to-market strategy?
A go-to-market (GTM) strategy is the plan for how a product reaches its customers and wins: which market and customers you target, what problem you solve for them, why they should choose you over the alternatives, at what price, through which channels, with which messages and resources, in what order, and how you will know it is working. It covers the decisions needed to launch a product or enter a new market, and it is narrower and more time-bound than a company's overall marketing strategy.
What is the difference between a go-to-market strategy and a marketing strategy?
A marketing strategy covers how a company or brand competes over the long run, across all its products and customers. A go-to-market strategy is tied to one moment: launching a specific product, entering a new market, or reaching a new customer group. It is more operational, includes sales, channels, regulatory and supply decisions, and has a clear start, sequence and set of launch milestones.
What are the key components of a go-to-market strategy?
Nine decisions: the market and the job to be done, the target customers, the value proposition and positioning, the offer and price, the channels and route to market, the messages and evidence, the sales and promotion model, the launch sequence and timing, and the measures of success. In regulated health markets add registration, pricing approval and compliance as constraints that shape every other decision.
How is a pharma go-to-market strategy different from a consumer goods one?
In pharma the product must be registered and, in many markets, priced by the regulator before it can be sold; promotion is restricted and must be evidence-based; and the person who chooses the product (a doctor or pharmacist) is often not the person who uses or pays for it. For prescription medicines, formulary and payer decisions decide access. OTC and consumer health products sit closer to consumer goods, with shopper, shelf and pharmacist recommendation playing a large role, but they still follow health product rules.
How long before launch should a go-to-market strategy be ready?
Start the strategy as soon as the product and the target market are known, usually well before regulatory approval, because registration, pricing, supply, listing and training all have long lead times. The detailed launch plan follows as approval gets closer. In Saudi Arabia, plan registration, SFDA pricing, distributor and pharmacy chain listing, and any hospital formulary work as separate tracks with their own timelines.
What KPIs should a go-to-market strategy track?
Track leading indicators first, because sales take time to show: availability (distribution, listings, formulary access), awareness and knowledge among target customers, trial or first prescriptions, repeat purchase or refills, then sales against forecast and market share. Pick a small set, define each one before launch, and review it on a fixed rhythm.
What are common go-to-market mistakes?
Targeting everyone instead of a clear first segment, launching before the product is available where customers buy, writing messages the regulator will not approve, underestimating the time needed for pricing and listings, spending the budget before there is evidence it works, and having no agreed measures of success.
What to Do Next
Take your next launch, or the product you know best, and fill in the one-page template in a single sitting. Mark every line you cannot answer in two sentences: those are the decisions to settle before the launch budget is approved. Then share the page with your sales, medical and finance colleagues and ask each of them to challenge one line.
For a full worked launch in one market, read the guide to launching an OTC product in Saudi Arabia. For the access track behind prescription launches, read the guide to market access. To turn the strategy into a plan with owners and dates, use the trade marketing plan template for the channel side and the brand plan guide for the brand side.
